1.05Open1.05Pre Close1 Volume3 Open Interest7.50Strike Price105.00Turnover218.94%IV8.58%PremiumMay 16, 2025Expiry Date0.45Intrinsic Value100Multiplier6DDays to Expiry0.61Extrinsic Value100Contract SizeAmericanOptions Type-0.5302Delta0.2011Gamma6.72Leverage Ratio-0.0681Theta-0.0007Rho-3.56Eff Leverage0.0036Vega
Seres Therapeutics Stock Discussion
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes. 85,742,623. 29,461,090 187,192. 0
Seres Therapeutics Inc - Ser-155 Receives Breakthrough Therapy and Fast Track Designations
Dow Jones· 3 mins ago
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Thursday, 9th January at 7:00 am
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres' live ...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
No comment yet